分子靶向药物吉非替尼治疗晚期非小细胞肺癌的疗效观察  

Clinical observation of molecular targeted drug Gefitinib in the treatment of advanced non-small cell lung cancer

作　　者：王淑世[1] WANG Shu-shi(The People＇ s Hospital of Zouping County,Zouping 256200,China)

机构地区：[1]山东省邹平县人民医院,256200

出　　处：《中国现代药物应用》2018年第17期1-3,共3页Chinese Journal of Modern Drug Application

摘　　要：目的探讨分子靶向药物吉非替尼治疗晚期非小细胞肺癌的疗效。方法 80例晚期非小细胞肺癌患者,随机分为对照组和观察组,每组40例。观察组患者给予分子靶向药物吉非替尼治疗,对照组患者给予常规化疗方案治疗,对比两组患者疾病控制情况和不良反应发生情况。结果观察组患者疾病控制率95.00%显著高于对照组的70.00%,差异具有统计学意义(P<0.05)。观察组患者不良反应发生率10.00%显著低于对照组40.00%,差异具有统计学意义(P<0.05)。结论分子靶向药物吉非替尼治疗晚期非小细胞肺癌的疗效显著,可有效控制疾病发展,且不良反应少,安全性较高,值得临床推广。Objective To investigate the efficacy of molecular targeted drug Gefitinib in the treatment of advanced non-small cell lung cancer. Methods A total of 80 patients with advanced non-small cell lung cancer were randomly divided into control group and observation group, 40 cases in each group. Patients in the observation group were treated with molecular targeted drug Gefitinib, patients in the control group were treated with conventional chemotherapy regimens. The condition of disease control and the occurrence of adverse reactions between the two groups were compared. Results The rate of disease control in the observation group was 95.00%, which was significantly higher than 70.00% in the control group, the difference was statistically significant（P〈0.05）. The incidence of adverse reactions in the observation group was 10.00%, which was significantly lower than 40.00% in the control group, the difference was statistically significant（P〈0.05）. Conclusion The curative effect of molecular targeted drug Gefitinib in the treatment of advanced non-small cell lung cancer is significant. It can effectively control the development of the disease, with less adverse reactions and high safety. It is worthy of clinical promotion.

关 键 词：分子靶向药物 吉非替尼 晚期 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]